s1 October 1964The Results of Indomethacin Therapy in Rheumatic Diseases.Bernard M. Norcross, M.D., F.A.C.P.Bernard M. Norcross, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-61-4-796_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIndomethacin is the first nonsteroid drug with marked anti-inflammatory, antipyretic, and analgesic activity since the introduction of phenylbutazone in the early 1950's. This compound is more potent than either cortisol or phenylbutazone when assayed by the granuloma pouch inhibition and the carrageenin-induced edema-inhibition techniques.More than 300 patients treated with Indomethacin during the past 2 years were observed for objective improvement and followed with extensive laboratory tests. The "side effects" included headaches, dizzyness, and gastrointestinal complaints.Indomethacin was more effective and associated with less serious toxicity than phenylbutazone or adrenal corticosteroids in the long-term management of rheumatoid or osteoarthritic patients.... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Buffalo, N. Y. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 October 1964Volume 61, Issue 4Page: 796-796KeywordsAnalgesicsCortisolDrugsGranulomasLaboratory testsToxicity Issue Published: 1 October 1964 PDF DownloadLoading ...